Purpose of this Study
We are doing this study to collect symptom and treatment experience data from patients with acute myelogenous leukemia (AML) being seen at the Duke Cancer Institute. We will add this data to a data registry and use it to identify quality improvement opportunities.
Who Can Participate?
Eligibility
Adults who:
- Are diagnosed with AML and currently receiving treatment
- Have the ability to complete online surveys using a cell phone, tablet, or computer
For more information about who can join this study, please contact the study team at sarah.lacinski@duke.edu
- Are diagnosed with AML and currently receiving treatment
- Have the ability to complete online surveys using a cell phone, tablet, or computer
For more information about who can join this study, please contact the study team at sarah.lacinski@duke.edu
Age Range
18-89
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
If you choose to join this study, you will fill out a baseline survey and weekly electronic surveys for at least 12 weeks. The surveys will ask you about the symptoms you experience as you go through your AML treatments.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
Real World Treatment Experience of Patients with Acute Myelogenous Leukemia and Multiple Myeloma Using Remote Symptom Monitoring
Principal Investigator
Thomas
Leblanc
Protocol Number
PRO00108428
NCT ID
NCT05974150
Phase
N/A
Enrollment Status
OPEN TO ACCRUAL